Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (441-450 of 706) with videos related to

Pageof 71
Sort By:
Journal of the American College of Cardiology|June 19, 2024
Randomized Trial of a Vascular Care Team vs Education for Patients With Peripheral Artery DiseaseConnie N Hess, Ashley Daffron, Mark R Nehler, et al.
Platelets|October 17, 2013
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO studyRobert F Storey, Stefan K James, Agneta Siegbahn, et al.
Journal of the American College of Cardiology|October 18, 2005
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trialKausik K Ray, Christopher P Cannon, Richard Cairns, et al.
Stroke|April 20, 2021
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-AnalysisZien Zhou, Meg J Jardine, Qiang Li, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 1, 2020
Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCIFrancesco Costa, Marco Valgimigli, Philippe Gabriel Steg, et al.
Circulation. Cardiovascular Quality and Outcomes|May 17, 2017
Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)Yashashwi Pokharel, Khaja Chinnakondepalli, Katherine Vilain, et al.
Diabetes, Obesity & Metabolism|February 15, 2022
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trialJennifer Y Barraclough, Jie Yu, Gemma A Figtree, et al.
The American Journal of Cardiology|November 6, 2013
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart diseaseAntonio M Gotto, Christopher P Cannon, Xiujiang Susie Li, et al.
JAMA Cardiology|June 16, 2021
Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the USChristopher P Cannon, James A de Lemos, Robert S Rosenson, et al.
Circulation. Cardiovascular Quality and Outcomes|January 20, 2011
Randomized trial of targeted performance feedback to facilitate quality improvement in acute myocardial infarction careKaren P Alexander, Tracy Y Wang, Shuang Li, et al.
Pageof 71

Showing results (441-450 of 706) with videos related to

Sort By:
Pageof 71
Journal of the American College of Cardiology|June 19, 2024
Randomized Trial of a Vascular Care Team vs Education for Patients With Peripheral Artery DiseaseConnie N Hess, Ashley Daffron, Mark R Nehler, et al.
Platelets|October 17, 2013
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO studyRobert F Storey, Stefan K James, Agneta Siegbahn, et al.
Journal of the American College of Cardiology|October 18, 2005
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trialKausik K Ray, Christopher P Cannon, Richard Cairns, et al.
Stroke|April 20, 2021
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-AnalysisZien Zhou, Meg J Jardine, Qiang Li, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 1, 2020
Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCIFrancesco Costa, Marco Valgimigli, Philippe Gabriel Steg, et al.
Circulation. Cardiovascular Quality and Outcomes|May 17, 2017
Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)Yashashwi Pokharel, Khaja Chinnakondepalli, Katherine Vilain, et al.
Diabetes, Obesity & Metabolism|February 15, 2022
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trialJennifer Y Barraclough, Jie Yu, Gemma A Figtree, et al.
The American Journal of Cardiology|November 6, 2013
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart diseaseAntonio M Gotto, Christopher P Cannon, Xiujiang Susie Li, et al.
JAMA Cardiology|June 16, 2021
Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the USChristopher P Cannon, James A de Lemos, Robert S Rosenson, et al.
Circulation. Cardiovascular Quality and Outcomes|January 20, 2011
Randomized trial of targeted performance feedback to facilitate quality improvement in acute myocardial infarction careKaren P Alexander, Tracy Y Wang, Shuang Li, et al.
Pageof 71